Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 15079

Reviews
Table of Contents - Year : 2017 | Month : June | Volume : 11 | Issue : 6 | Page : OE01 - OE04

Basic Concepts and Clinical Outcomes of Drug-eluting Balloons for Treatment of Coronary Artery Disease: An Overview OE01-OE04

Ramakrishna C. D., Bhargav A. Dave, Pankaj S. Kothavade, Kajal J. Joshi, Ashok S. Thakkar

Correspondence
Dr. Ashok S. Thakkar,
Ph D (Pharmacology), Head of Department of Clinical Research, Meril Life Sciences Pvt. Ltd.
Survey No.135/139, Bilakhia House, Muktanand Marg, Chala, Vapi 396 191, Gujarat, India.
E-mail: ashok.thakkar@merillife.com

The technology of percutaneous coronary intervention for atherosclerotic coronary artery disease has evolved considerably since its inception. Though Drug-Eluting Stent (DES) reduces the rate of restenosis, long-term safety outcomes and persistent restenosis in complex lesion subset remain area of concern. Recently, Drug-Eluting Balloon (DEB) represents a novel treatment strategy for atherosclerotic coronary artery disease. DEB demonstrated its added value in preclinical studies. Inspired by these results, several clinical trials particularly in complex lesion subsets have been started to explore the value of this novel treatment strategy in a broader range of lesions. This review would summarise material compositions and different characteristics and clinical outcomes of currently available DEB.